文献速递淋巴瘤贫血与红细胞疾病

γδT细胞大颗粒淋巴细胞白血病17例临床与实验室分析

[Clinical and laboratory analysis of 17 patients with γδT-cell large granular lymphocyte leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

回顾性对比17例γδT-LGLL与91例αβT-LGLL患者,发现除γδT-LGLL更常见CD4(−)/CD8(−)双阴性表型外,两者临床及实验室特征相似;环孢素A为基础治疗4个月总体有效率35%。

要点

  • γδT-LGLL与αβT-LGLL临床及实验室特征总体相似。
  • γδT-LGLL典型免疫表型为CD4(−)/CD8(−)双阴性。
  • 环孢素A单用或联合泼尼松治疗4个月总体有效率35%。

核心结论

  • γδT-LGLL是一种少见的成熟T淋巴细胞增殖性疾病,除CD4(−)/CD8(−)双阴性表型外,临床及实验室表现与αβT-LGLL无显著差异。
  • 环孢素A可作为γδT-LGLL的首选治疗药物。

研究设计与样本

  • 回顾性分析中国医学科学院血液病医院贫血诊疗中心2009年1月至2019年1月17例γδT-LGLL患者,与同期91例αβT-LGLL患者对比。

主要发现

  • 17例γδT-LGLL患者中位年龄54岁(范围25~73岁),最常见就诊症状为贫血。
  • 脾大在γδT-LGLL和αβT-LGLL分别为41%和44%,肝大分别为12%和5%,淋巴结肿大分别为6%和8%。
  • 抗核抗体阳性率分别为59%和45%,风湿因子阳性率分别为6%和10%。
  • 两组中性粒细胞绝对值、淋巴细胞绝对值、HGB及PLT差异均无统计学意义(P值均>0.05)。
  • γδT-LGLL典型免疫分型为CD3(+)/CD4(−)/CD8(−)/CD57(+)/TCRγδ(+),CD4(−)/CD8(−)双阴性表型显著多于αβT-LGLL(P<0.001)。

关键数值与推荐

  • 17例γδT-LGLL中1例口服泼尼松,3例口服环孢素A,13例口服环孢素A联合泼尼松。
  • 治疗4个月后2例完全缓解,4例部分缓解,总体有效率35%。

临床怎么用

  • 对疑似γδT-LGLL患者应行免疫分型检测,关注CD4(−)/CD8(−)双阴性表型。
  • 环孢素A可考虑作为γδT-LGLL一线治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the difference of the clinical and laboratory characteristics between γδ T-cell large granular lymphocyte leukemia (γδT-LGLL) and αβ T-cell large granular lymphocyte leukemia (αβT-LGLL) . Methods: The clinical and laboratory characteristics of 17 patients with γδT-LGLL and 91 patients with αβT-LGLL in the department of therapeutic center of anemia of enrolled in our hospital from January 2009 to January 2019 were retrospectively analyzed. Results: The median age of the 17 patients with γδT-LGLL was 54 years (range, 25-73 years) , the most common presenting symptom was anemia. In comparison with αβT-LGLL patients, splenomegaly was common (41% and 44%, respectively) , whereas hepatomegaly (12% and 5%, respectively) and lymphadenopathy (6% and 8%, respectively) were rare. The positive rates of antinuclear antibody (59% and 45%, respectively) were high, whereas the positive rates of rheumatoid factor (6% and 10%, respectively) were rare for both groups. There were no differences on peripheral blood counts between the two groups. However, γδT-LGLL patients were found to be predominantly expressed a CD4(-)/CD8(-) phenotype. Steroid therapy with prednisone was used alone as first-line therapy for 1 patient. Cyclosporin A (CsA) was used alone as first-line therapy for 3 patients. CsA in combination with steroids were administered in 13 patients. After 4 months treatment, 2 patients acquired complete response, 4 patients acquired partial response, the overall response was 35%. Conclusion: γδT-LGLL is a rare mature T-lymphocyte proliferative disease. Clinical and laboratory characteristics were quite similar for γδT-LGLL in compare with αβT-LGLL. γδT-LGLL predominantly expressed a CD4(-)/CD8(-) phenotype. The data presented here indicate the CsA is an effective option for the first-line treatment of γδT-LGLL. 目的: 比较γδT细胞大颗粒淋巴细胞白血病(γδT-LGLL)与αβT细胞大颗粒淋巴细胞白血病(αβT-LGLL)的临床及实验室特征。 方法: 回顾性分析中国医学科学院血液病医院贫血诊疗中心2009年1月至2019年1月17例γδT-LGLL患者的临床及实验室结果,与同时期91例αβT-LGLL患者进行对比。 结果: 17例γδT-LGLL患者中位年龄54(25~73)岁,10例就诊原因为贫血。γδT-LGLL与αβT-LGLL一致,脾大(41%和44%)较为常见,肝大(12%和5%)及淋巴结肿大(6%和8%)较为少见;两者均有较高的抗核抗体阳性率(59%和45%),较低的风湿因子阳性率(6%和10%);两者中性粒细胞绝对值、淋巴细胞绝对值、HGB及PLT差异均无统计学意义(P值均>0.05)。γδT-LGLL患者的典型免疫分型为CD3(+)/CD4(−)/CD8(−)/CD57(+)/TCRγδ(+),CD4(−)/CD8(−)双阴性表型显著多于αβT-LGLL患者(P<0.001)。17例γδT-LGLL患者有1例口服泼尼松治疗,3例口服环孢素A治疗,13例口服环孢素A联合泼尼松治疗,治疗4个月后2例获得完全缓解,4例获得部分缓解,总体有效率为35%。 结论: γδT-LGLL是一种少见的成熟T淋巴细胞增殖性疾病,其临床及实验室表现与αβT-LGLL相比除CD4(−)/CD8(−)双阴性表型外均无显著差异。环孢素A可作为γδT-LGLL的首选治疗药物。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhu YM, Gao QY, Hu J, et al. [Clinical and laboratory analysis of 17 patients with γδT-cell large granular lymphocyte leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32135626. doi:10.3760/cma.j.issn.0253-2727.2020.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。